112 related articles for article (PubMed ID: 31423895)
1. Characterization of the dehydrogenase-reductase DHRS2 and its involvement in histone deacetylase inhibition in urological malignancies.
Müller MR; Burmeister A; Skowron MA; Stephan A; Söhngen C; Wollnitzke P; Petzsch P; Alves Avelar LA; Kurz T; Köhrer K; Levkau B; Nettersheim D
Exp Cell Res; 2024 Jun; 439(1):114055. PubMed ID: 38704080
[TBL] [Abstract][Full Text] [Related]
2. Genetic dissection of histone deacetylase requirement in tumor cells.
Haberland M; Johnson A; Mokalled MH; Montgomery RL; Olson EN
Proc Natl Acad Sci U S A; 2009 May; 106(19):7751-5. PubMed ID: 19416910
[TBL] [Abstract][Full Text] [Related]
3. Dehydrogenase/reductase SDR family member 2 silencing sensitizes an oxaliplatin‑resistant cell line to oxaliplatin by inhibiting excision repair cross‑complementing group 1 protein expression.
Li JM; Jiang GM; Zhao L; Yang F; Yuan WQ; Wang H; Luo YQ
Oncol Rep; 2019 Nov; 42(5):1725-1734. PubMed ID: 31436301
[TBL] [Abstract][Full Text] [Related]
4. The bioinformatics aspects of gene screening of HT-29, human colon cell line treated with caffeic acid.
Rezaei-Tavirani M; Rezaei Tavirani M; Zamanian Azodi M
Gastroenterol Hepatol Bed Bench; 2019; 12(3):246-253. PubMed ID: 31528309
[TBL] [Abstract][Full Text] [Related]
5. Emerging roles of dehydrogenase/reductase member 2 (DHRS2) in the pathology of disease.
Li Z; Liu H; Bode A; Luo X
Eur J Pharmacol; 2021 May; 898():173972. PubMed ID: 33652058
[TBL] [Abstract][Full Text] [Related]
6. Regulatory mechanism of DHRS2-modified human umbilical cord mesenchymal stem cells-derived exosomes in prostate cancer cell proliferation and apoptosis.
Wu X; Zeng Z; Peng K; Ren D; Zhang L
Tissue Cell; 2023 Jun; 82():102078. PubMed ID: 37060745
[TBL] [Abstract][Full Text] [Related]
7. Auxiliary Diagnosis and Prognostic Value of Dehydrogenase/Reductase 2 (DHRS2) in Various Tumors.
An Z; Bo W; Qin J; Jiang L; Jiang J
Iran J Public Health; 2023 Jun; 52(6):1150-1160. PubMed ID: 37484140
[TBL] [Abstract][Full Text] [Related]
8. Factor-specific generative pattern from large-scale drug-induced gene expression profile.
Ahn SH; Kim JH
Sci Rep; 2023 Apr; 13(1):6339. PubMed ID: 37072452
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Synergistic Potential of Simultaneous Pan- or Isoform-Specific BET and SYK Inhibition in B-Cell Lymphoma: An In Vitro Approach.
Sender S; Sultan AW; Palmer D; Koczan D; Sekora A; Beck J; Schuetz E; Taher L; Brenig B; Fuellen G; Junghanss C; Murua Escobar H
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230614
[No Abstract] [Full Text] [Related]
10. Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells.
Smalley JP; Baker IM; Pytel WA; Lin LY; Bowman KJ; Schwabe JWR; Cowley SM; Hodgkinson JT
J Med Chem; 2022 Apr; 65(7):5642-5659. PubMed ID: 35293758
[TBL] [Abstract][Full Text] [Related]
11. Ovarian cancer: epigenetics, drug resistance, and progression.
Xie W; Sun H; Li X; Lin F; Wang Z; Wang X
Cancer Cell Int; 2021 Aug; 21(1):434. PubMed ID: 34404407
[TBL] [Abstract][Full Text] [Related]
12. Identification of gene co-expression modules and hub genes associated with the invasiveness of pituitary adenoma.
Zhou Y; Fu X; Zheng Z; Ren Y; Zheng Z; Zhang B; Yuan M; Duan J; Li M; Hong T; Lu G; Zhou D
Endocrine; 2020 May; 68(2):377-389. PubMed ID: 32342269
[TBL] [Abstract][Full Text] [Related]
13. Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer.
Han Y; Wang Z; Sun S; Zhang Z; Liu J; Jin X; Wu P; Ji T; Ding W; Wang B; Gao Q
Epigenetics; 2020; 15(1-2):122-133. PubMed ID: 31423895
[TBL] [Abstract][Full Text] [Related]
14. DHRS2 inhibits cell growth and metastasis in ovarian cancer by downregulation of CHKα to disrupt choline metabolism.
Li Z; Tan Y; Li X; Quan J; Bode AM; Cao Y; Luo X
Cell Death Dis; 2022 Oct; 13(10):845. PubMed ID: 36192391
[TBL] [Abstract][Full Text] [Related]
15. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
16. Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells.
Kwiecińska P; Wróbel A; Taubøll E; Gregoraszczuk EŁ
Toxicol Lett; 2014 Jan; 224(2):225-32. PubMed ID: 24200999
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
